Literature DB >> 1718968

A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active.

D B Evans1, K Brawn, M R Deibel, W G Tarpley, S K Sharma.   

Abstract

We report here a human immunodeficiency virus type 1 (HIV-1) recombinant ribonuclease H (RNase H) domain engineered to contain an N-terminal tag for its isolation by affinity chromatography. The purified protein is active in hydrolyzing RNA-DNA hybrids in two separate in vitro assay systems. In light of recent reports of similar HIV-1 RNase H domains which were enzymatically inactive (Becerra, S. P., Clore, G. M., Gronenborn, A. M., Karlstrom, A. R., Stahl, S. J., Wilson, S.M., and Wingfield, P.T. (1990) FEBS Lett. 270, 76-80; Hostomsky, Z., Hostomska, Z., Hudson, G. O., Moomaw, E. W., and Nodes, B. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1148-1152), our results suggest that a stretch of 20-30 residues immediately upstream of the polymerase-RNase H junction (residues 440-441 of HIV-1 reverse transcriptase) may be required for productive binding and alignment of the hybrid RNA-DNA substrate. The active HIV-1 RNase H domain is suitable for structural analysis, thereby providing a unique active molecule to better understand the structural basis for the functional organization of RNase associated with the HIV-1 reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718968

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843.

Authors:  I W Althaus; R J LeMay; A J Gonzales; M R Deibel; S K Sharma; F J Kezdy; L Resnick; M E Busso; P A Aristoff; F Reusser
Journal:  Experientia       Date:  1992-12-01

2.  HIV-1 Reverse Transcriptase Polymerase and RNase H (Ribonuclease H) Active Sites Work Simultaneously and Independently.

Authors:  An Li; Jiawen Li; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

3.  Crystal structure of the moloney murine leukemia virus RNase H domain.

Authors:  David Lim; G Glenn Gregorio; Craig Bingman; Erik Martinez-Hackert; Wayne A Hendrickson; Stephen P Goff
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  A Ty1 reverse transcriptase active-site aspartate mutation blocks transposition but not polymerization.

Authors:  O Uzun; A Gabriel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase.

Authors:  Anoma Somasunderam; Monique R Ferguson; Daniel R Rojo; Varatharasa Thiviyanathan; Xin Li; William A O'Brien; David G Gorenstein
Journal:  Biochemistry       Date:  2005-08-02       Impact factor: 3.162

Review 6.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

7.  Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitors.

Authors:  Angela Corona; Anna Schneider; Kristian Schweimer; Paul Rösch; Birgitta M Wöhrl; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

8.  Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain.

Authors:  J S Smith; M J Roth
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

10.  Evidence from CD spectra that d(purine).r(pyrimidine) and r(purine).d(pyrimidine) hybrids are in different structural classes.

Authors:  S H Hung; Q Yu; D M Gray; R L Ratliff
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.